AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 MAR 29 - (NewsRx.com & NewsRx.net) -- by Jennifer Webb, staff medical writer - Fatty liver and intra-abdominal fat accumulation are common in obese patients receiving tamoxifen for the treatment of breast cancer, study results indicate.
"Tamoxifen is a nonsteroidal anti-estrogenic drug used for adjuvant treatment of breast cancer and recently as a chemo-preventative agent for breast cancer and, on an investigational basis, for other cancers," reported J.G. Kral and colleagues from the Southern University of New York.
The researchers noted that case reports of hypertriglyceridemia and fatty liver disease have been demonstrated in tamoxifen users.
A cross-sectional study of 32 women who were taking tamoxifen and 39 controls was conducted to evaluate steatosis and distribution of adipose tissue. Computed tomography scan revealed more visceral adipose tissue (VAT) and more liver fat in the tamoxifen users than in the controls, reported Kral et al. ("Relationships between tamoxifen use, liver fat and body fat distribution in ...